logo_tau.png
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology
21 oct. 2022 16h01 HE | Alpha Tau Medical Ltd.
- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the vulva at Addenbrookes Hospital in Cambridge - - Health Canada...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING LAW FIRM, Encourages Terra Tokens Investors With Losses to Secure Counsel Before Important August 19 Deadline in Securities Class Action – UST, LUNA, KRT, ANC, WHALE, ASTRO, APOLLO, XDEFI, MINE, aUST, vUST, MIR, mBTC, mETH, mVIXY, mTSLA, UST-mVIXY-LP, bLUNA-LUNA-LP, XDEFI-UST-LP, bLUNA, bETH
02 août 2022 15h00 HE | The Rosen Law Firm PA
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Terra Tokens, including UST, LUNA, KRT, ANC, WHALE, ASTRO, APOLLO, XDEFI,...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING LAW FIRM, Encourages Terra Tokens Investors to Secure Counsel Before Important Deadline in Securities Class Action – UST, LUNA, KRT, ANC, WHALE, ASTRO, APOLLO, XDEFI, MINE, aUST, vUST, MIR, mBTC, mETH, mVIXY, mTSLA, UST-mVIXY-LP, bLUNA-LUNA-LP, XDEFI-UST-LP, bLUNA, bETH
28 juil. 2022 13h18 HE | The Rosen Law Firm PA
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Terra Tokens, including UST, LUNA, KRT, ANC, WHALE, ASTRO, APOLLO, XDEFI,...
Poster
Fantagio to Host Its First Music Hackathon Starting April 25 for Its Upcoming Global Launch of an NFT Meta Idol, Composers Around the World Can Participate as Contestants
20 avr. 2022 02h00 HE | Fantagio
SINGAPORE, April 20, 2022 (GLOBE NEWSWIRE) -- Fantagio, a KOSDAQ-listed South Korean entertainment powerhouse, announced its plans to host Fantagio Music Hackathon, a global audition for aspiring...
Featured Image for Videra Surgical Inc.
Study Demonstrates Superiority of VeraForm® Marker Over Clips for Tumor Bed Delineation Accuracy
28 oct. 2021 15h00 HE | Videra Surgical
SAN FRANCISCO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Videra Surgical Inc., the developer of the novel adaptable tumor bed marker VeraForm® for breast cancer surgery, announced the presentation of an...
akesis-logo-2-CMYK.jpg
Gerry Vantellingen Joins Akesis as President
22 oct. 2020 10h39 HE | Akesis
CONCORD, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Gerry Vantellingen has joined Akesis as President, the company announced today. Vantellingen has held a variety of global leadership positions with...
akesis-logo-2-CMYK.jpg
Akesis Galaxy™ SRS System Receives 510(k) Clearance
13 sept. 2019 08h00 HE | Akesis
CONCORD, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) -- The Akesis Galaxy™, a gamma stereotactic radiosurgery system (SRS) with continuous 360o rotational technology, has received 510(k) clearance from...
aa astro.jpg
BCSC removes CTO in Canada
23 oct. 2018 10h21 HE | Astro Aerospace Ltd.
Dallas, Texas, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Astro Aerospace Ltd. (the “Company” or “Astro”) (OTCQB: ASDN) and its wholly-owned subsidiaries, announces that effective __Monday Oct 22, 2018, the...
Nanobiotix présenter
Nanobiotix présentera les résultats positifs de son étude de phase II/III évaluant NBTXR3 dans les Sarcomes Des Tissus Mous (STM) et de ses autres études de phase I/II aux prochains congrès annuels de l’ESMO et de l’ASTRO
26 sept. 2018 02h00 HE | NANOBIOTIX
  NANOBIOTIX PRESENTERA LES RESULTATS POSITIFS DE SON ETUDE DE PHASE II/III EVALUANT NBTXR3 DANS LES SARCOMES DES TISSUS MOUS (STM) ET DE SES AUTRES ETUDES DE PHASE I/II AUX PROCHAINS CONGRES...
Nanobiotix to presen
Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with Soft Tissue Sarcoma (STS) and other ongoing phase I/II trials at upcoming ESMO and ASTRO annual conferences
26 sept. 2018 02h00 HE | NANOBIOTIX
  NANOBIOTIX TO PRESENT POSITIVE RESULTS FROM ITS PHASE II/III CLINICAL TRIAL OF NBTXR3 IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND OTHER ONGOING PHASE I/II TRIALS AT UPCOMING ESMO AND ASTRO...